Cardiovascular Toxicology

The effects of neuropeptide Y overexpression on the mouse model of doxorubicin-induced cardiotoxicity

Minttu Mattila\textsuperscript{1,2}, Mirva Söderström\textsuperscript{1}, Liisa Ailanen\textsuperscript{1}, Eriika Savontaus\textsuperscript{1,4}, Mikko Savontaus\textsuperscript{5}

\textsuperscript{1}Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland
\textsuperscript{2}Drug Research Doctoral Programme, University of Turku, Turku, Finland
\textsuperscript{3}Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland
\textsuperscript{4}Clinical pharmacology, Turku University Hospital, Turku, Finland
\textsuperscript{5}Heart Centre, Turku University Hospital and University of Turku, Turku, Finland

Correspondence: Eriika Savontaus, eriika.savontaus@utu.fi
Online Resource 1 Relative mRNA expression levels in the hearts in saline and doxorubicin (DOX) -treated wild-type (WT) and NPY-OEββ (NPY-OE) mice, a) B-type natriuretic peptide (Bnp) level, b) matrix metalloproteinase (Mmp13) level, c) interleukin-1β (Il-1β) level, d) transforming growth factor-β (Tgf-β) level, e) tumor necrosis factor-α (Tnf-α) level, f) α-smooth muscle actin (α-Sma) level, g) beta-1 adrenergic receptor (Beta1R) level, h) myosin heavy chain-α (Mhc-α) level, i) peroxisome proliferator-activated receptor-γ coactivator-1α (Pgc-1a) level. Values are presented as means ± SEM (n = 6-8/group)